How China applicants could avoid the sintilimab scenario
A US adcom savages sintilimab, but the biggest problems identified might be sintilimab-specific.
Crucial clinical events for the smaller players
Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
No fast way to eighth place for Incyte
Retifanlimab gets knocked back by a US adcom. Could a rival now beat it to become the eighth anti-PD-(L)1 to reach the US market?
EQRX vows to slash drug prices where others have failed
Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.